MRNA · available-data snapshot
Moderna, Inc. (MRNA): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Moderna, Inc. (MRNA); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for MRNA?
We do not publish a fair value for Moderna, Inc.. What we can say from its filings and market data is below.
What is MRNA's TickerWorth Score?
Scores lower than almost every company we compare it with
Compared with Healthcare companies in US
Its strongest point: recent price trend has been strong. Its weakest: profitability is weak.
- Value · 17 of 100
Cheaper than 17% of Healthcare companies in US
- Price vs worth · 0 of 100
- Quality · 7 of 100
More profitable than 7% of Healthcare companies in US
- Financial health · 67 of 100
Financially stronger than 67% of Healthcare companies in US
- Growth · 23 of 100
Growing faster than 23% of Healthcare companies in US
- Momentum · 95 of 100
Outperformed 95% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $218.01
- Market cap
- $87,
037, 419, 520 - 52-week high
- $242.29
- 52-week low
- $22.28
- Currency
- USD
- Exchange
- NasdaqGS
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Moderna, Inc. (MRNA) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, MRNA trades at a recent price of $218.01, a market capitalisation of about $87,037,419,520, sitting 89% of the way up its 52-week range ($22.28–$242.29), on the NasdaqGS.
The standard alternative to a DCF is relative valuation — comparing MRNA's trading multiples against its direct industry peers. Here that gives P/B of 12.9× (richer than the peer median of 6.3×); P/S of 39.1× (richer than the peer median of 6.1×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. MRNA shows a price-to-book (P/B) of 12.87 and book value of $16.95 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. MRNA is in an up-trend (price above both its 50- and 200-day averages), trading -10.0% from its 52-week high. Over the past year the stock is +700.3%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
MRNA vs peers
Direct industry peers.
| Multiple | MRNA | Peer median | Read |
|---|---|---|---|
| P/B | 12.9× | 6.3× | richer than |
| P/S | 39.1× | 6.1× | richer than |
What does Moderna, Inc. do?
What does it do?
Moderna is a biotechnology company that develops messenger RNA medicines. Its products include vaccines for respiratory diseases (COVID-19, RSV, influenza), latent viral infections (cytomegalovirus, Epstein-Barr virus, HIV), and other conditions, as well as oncology therapeutics and rare disease treatments.
How does it make money?
Moderna generates revenue from sales of its mRNA-based vaccines and therapeutic products. The company reported total revenue of $2.23 billion, though it currently operates at a loss with a gross margin of -66% and net margin of -141%.
Is it financially healthy?
Moderna shows mixed financial health: it has a low debt-to-equity ratio of 0.19 and a strong current ratio of 2.30, indicating solid short-term liquidity and moderate leverage. However, the company is unprofitable with negative operating and net margins, meaning it is currently losing money on its operations.
Who at MRNA filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Hoge Stephen | President | Option exercise | $933,478.92 | Form 4 for Hoge Stephen (opens sec.gov in a new tab) | |
| Hoge Stephen | President | Open-market sale | $8,640,084.40 | Form 4 for Hoge Stephen (opens sec.gov in a new tab) | |
| Hoge Stephen | President | Option exercise | $933,491.13 | Form 4 for Hoge Stephen (opens sec.gov in a new tab) | |
| Hoge Stephen | President | Open-market sale | $8,277,085.78 | Form 4 for Hoge Stephen (opens sec.gov in a new tab) | |
| Hoge Stephen | President | Open-market sale | $96,367.50 | Form 4 for Hoge Stephen (opens sec.gov in a new tab) | |
| Mock James M | Chief Financial Officer | Option exercise | — | Form 4 for Mock James M (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
How does MRNA compare with its peers?
People who read MRNA also read
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.